CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Q Fever Vaccine (NDBR 105biological
Likely dose
Q Fever Vaccine (NDBR 105 0.1 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00584454
NCT00584454Phase 2Completed
CompareCT.gov

Continued Evaluation of the Safety of Q Fever Vaccine, Phase I, Inactivated, Freeze Dried, NDBR 105, in Those at Risk of Exposure to Coxiella Burnetii, A Phase 2 Study

U.S. Army Medical Research and Development Command·interventional·Posted Jan 2, 2008·Updated Jan 3, 2020

In Brief

A Phase 2 clinical trial evaluating Q Fever Vaccine (NDBR 105 for Q Fever. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety of Q Fever vaccine, NDBR 105, and collect data on incidence of occupational Q Fever infection in at risk personnel.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsQ Fever
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2, 2008
Enrollment StartFeb 1, 2006
Primary CompletionJul 1, 2009
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 18.5 years ago

Interventions

Q Fever Vaccine (NDBR 105biological

Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.